Mutsunori Shirai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mutsunori Shirai has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Teruko Nakazawa
Departments of Microbiology1, Neurosurgery2 and Pediatrics3, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan 4Department of Clinical Research, National Sanyo Hospital, Ube, Yamaguchi, 755-0241, Japan 5Saiseikai General Hospital, Shimonoseki, Yamaguchi, 751-0823, Japan
4 shared publicationsHiroshi Matsushima
Departments of Microbiology1, Neurosurgery2 and Pediatrics3, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan 4Department of Clinical Research, National Sanyo Hospital, Ube, Yamaguchi, 755-0241, Japan 5Saiseikai General Hospital, Shimonoseki, Yamaguchi, 751-0823, Japan
2 shared publicationsKazunobu Ouchi
Departments of Microbiology1, Neurosurgery2 and Pediatrics3, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan 4Department of Clinical Research, National Sanyo Hospital, Ube, Yamaguchi, 755-0241, Japan 5Saiseikai General Hospital, Shimonoseki, Yamaguchi, 751-0823, Japan
2 shared publicationsRyutaro Fujinaga
Department of Microbiology, Yamaguchi University School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan
2 shared publicationsA Miyamoto
1 shared publicationAtsushi Nakazawa
Department of Biochemistry, School of Medicine
1 shared publication
Latest Publications
- Open Access
- 15 October 2003
- Published by American Physical Society (APS) in Physical Review Special Topics - Accelerators and Beams
- Vol. 6 (10) , 103201
Possibility of comb-type rf shield structure for high-current accelerators
A novel rf shield structure for bellows chambers or gate valves in high-current accelerators is proposed. The rf shield has no thin fingers, but nested comb teeth instead at the inner surface of the beam duct. The comb-type rf shield has a higher thermal strength structurally than the conventional finger-type one. A simulation also indicates its lower impedance. Especially, the leak of a TE modelike higher order mode through the axial slits, which causes mainly heating of these components, is almost suppressed due to thick teeth. An abrasion test in a vacuum using a test piece of the comb-type rf shield shows less dust generation compared to the finger type. Another preliminary test transmitting 508 MHz microwaves through a prototype rf shield in the atmosphere found no abnormal heating or arcing. A trial model of bellows chambers with the comb-type rf shield will be installed and tested using a real beam in the KEK -factory positron ring this year.- 15 October 2003
- Published by American Physical Society (APS) in Physical Review Special Topics - Accelerators and Beams
- Vol. 6 (10) , 103201
Open AccessPossibility of comb-type rf shield structure for high-current accelerators
A novel rf shield structure for bellows chambers or gate valves in high-current accelerators is proposed. The rf shield has no thin fingers, but nested comb teeth instead at the inner surface of the beam duct. The comb-type rf shield has a higher thermal strength structurally than the conventional finger-type one. A simulation also indicates its lower impedance. Especially, the leak of a TE modelike higher order mode through the axial slits, which causes mainly heating of these components, is almost suppressed due to thick teeth. An abrasion test in a vacuum using a test piece of the comb-type rf shield shows less dust generation compared to the finger type. Another preliminary test transmitting 508 MHz microwaves through a prototype rf shield in the atmosphere found no abnormal heating or arcing. A trial model of bellows chambers with the comb-type rf shield will be installed and tested using a real beam in the KEK -factory positron ring this year. - Open Access
- 1 May 2003
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 52 (5) , 409-415
Aspirin inhibits Chlamydia pneumoniae-induced NF-κB activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth
Infection with Chlamydia pneumoniae has been implicated as a potential risk factor for atherosclerosis. This study was designed to investigate the mechanisms of the anti-chlamydial activity of aspirin. A reporter gene assay for NF-κB activity, immunoblot analysis for cyclo-oxygenase (COX)-2 and radioimmunoassay for prostaglandin E2 (PGE2) were performed. Following infection of HEp-2 cells with C. pneumoniae, NF-κB was activated, COX-2 was induced and PGE2 was elevated. Aspirin inhibited NF-κB activation at a concentration of 0.1 mM, partially inhibited COX-2 induction and blocked PGE2 synthesis completely. In addition, high doses of aspirin (1 and 2 mM) inhibited chlamydial growth in HEp-2 cells, decreasing the number and size of inclusion bodies; this effect could be overcome by adding tryptophan to the culture. Indomethacin also blocked the synthesis of PGE2, but had no effect on COX-2 expression or chlamydial growth. These results indicate that aspirin not only has an anti-inflammatory activity through prevention of NF-κB activation but also has anti-chlamydial activity at high doses, possibly through depletion of tryptophan in HEp-2 cells.
- 1 May 2003
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 52 (5) , 409-415
Open AccessAspirin inhibits Chlamydia pneumoniae-induced NF-κB activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth
Infection with Chlamydia pneumoniae has been implicated as a potential risk factor for atherosclerosis. This study was designed to investigate the mechanisms of the anti-chlamydial activity of aspirin. A reporter gene assay for NF-κB activity, immunoblot analysis for cyclo-oxygenase (COX)-2 and radioimmunoassay for prostaglandin E2 (PGE2) were performed. Following infection of HEp-2 cells with C. pneumoniae, NF-κB was activated, COX-2 was induced and PGE2 was elevated. Aspirin inhibited NF-κB activation at a concentration of 0.1 mM, partially inhibited COX-2 induction and blocked PGE2 synthesis completely. In addition, high doses of aspirin (1 and 2 mM) inhibited chlamydial growth in HEp-2 cells, decreasing the number and size of inclusion bodies; this effect could be overcome by adding tryptophan to the culture. Indomethacin also blocked the synthesis of PGE2, but had no effect on COX-2 expression or chlamydial growth. These results indicate that aspirin not only has an anti-inflammatory activity through prevention of NF-κB activation but also has anti-chlamydial activity at high doses, possibly through depletion of tryptophan in HEp-2 cells.
- Open Access
- 1 November 2002
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 50 (6) , 849-856
A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori
Reports on the isolation of amoxicillin-resistant Helicobacter pylori are increasing worldwide, which may cause serious problems in eradication therapy. To elucidate the mechanism of amoxicillin resistance of H. pylori, penicillin-binding proteins (PBPs) of amoxicillin-resistant strains isolated in Korea were analysed. Three PBPs (66, 63 and 60 kDa) were identified in both amoxicillin-resistant and -susceptible strains using biotinylated ampicillin, and the PBP profiles were very similar irrespective of the difference in amoxicillin susceptibility. We obtained clones with moderate resistance from an amoxicillin-susceptible strain, HPK5, by transformation with genomic DNA from an amoxicillin-resistant strain, HPA116. In a resistance-induced clone, HPO1, the affinity of PBP1 for amoxicillin was reduced. The pbp1 genes from HPA116, HPO1 and HPK5 were cloned and sequenced. The nucleotide sequences of pbp1 from HPA116 and HPO1 were almost identical, whereas that of HPK5 was quite different. Both the ORFs of HPA116 and HPO1 pbp1 have four substitutions and one insertion of amino acid residues compared with those of HPK5 and other sensitive strains. All the mutations, except one, are in the C-terminal half of the 659-amino-acid sequence containing the penicillin-binding modules. DNA fragments containing either full-length or a C-terminal half of pbp1 could transform HPK5 to have resistance, indicating that changes in the penicillin-binding core of PBP1 are involved in the amoxicillin resistance of H. pylori isolated in Korea.
- 1 November 2002
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 50 (6) , 849-856
Open AccessA change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori
Reports on the isolation of amoxicillin-resistant Helicobacter pylori are increasing worldwide, which may cause serious problems in eradication therapy. To elucidate the mechanism of amoxicillin resistance of H. pylori, penicillin-binding proteins (PBPs) of amoxicillin-resistant strains isolated in Korea were analysed. Three PBPs (66, 63 and 60 kDa) were identified in both amoxicillin-resistant and -susceptible strains using biotinylated ampicillin, and the PBP profiles were very similar irrespective of the difference in amoxicillin susceptibility. We obtained clones with moderate resistance from an amoxicillin-susceptible strain, HPK5, by transformation with genomic DNA from an amoxicillin-resistant strain, HPA116. In a resistance-induced clone, HPO1, the affinity of PBP1 for amoxicillin was reduced. The pbp1 genes from HPA116, HPO1 and HPK5 were cloned and sequenced. The nucleotide sequences of pbp1 from HPA116 and HPO1 were almost identical, whereas that of HPK5 was quite different. Both the ORFs of HPA116 and HPO1 pbp1 have four substitutions and one insertion of amino acid residues compared with those of HPK5 and other sensitive strains. All the mutations, except one, are in the C-terminal half of the 659-amino-acid sequence containing the penicillin-binding modules. DNA fragments containing either full-length or a C-terminal half of pbp1 could transform HPK5 to have resistance, indicating that changes in the penicillin-binding core of PBP1 are involved in the amoxicillin resistance of H. pylori isolated in Korea.
- 1 January 2001
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 7 (3) , 180-185
Analysis of the serological response to Chlamydia pneumoniae in patients with ischemic heart disease by recombinant MOMP-ELISA
- 1 January 2001
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 7 (3) , 180-185
Analysis of the serological response to Chlamydia pneumoniae in patients with ischemic heart disease by recombinant MOMP-ELISA
- 1 January 2001
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 7 (3) , 148-155
Allelic exchange mutagenesis of rpoN encoding RNA-polymerase σ54 subunit in Helicobacter pylori
- 1 January 2001
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 7 (3) , 148-155
Allelic exchange mutagenesis of rpoN encoding RNA-polymerase σ54 subunit in Helicobacter pylori
- 15 June 2000
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 28 (12) , 2311-2314
Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA
Chlamydia pneumoniae is a widespread pathogen of humans causing pneumonia and bronchitis. There are many reports of an association between C.PNEUMONIAE: infection and atherosclerosis. We determined the whole genome sequence of C.PNEUMONIAE: strain J138 isolated in Japan in 1994 and compared it with the sequence of strain CWL029 isolated in the USA before 1987. The J138 circular chromosome consists of 1 226 565 nt (40.7% G+C) with 1072 likely protein-coding genes that is 3665 nt shorter than the CWL029 genome. Plasmids, phage- or transposon-like sequences were not identified. The overall genomic organization, gene order and predicted proteomes of the two strains are very similar, suggesting a high level of structural and functional conservation between the two unrelated isolates. The most conspicuous differences in the J138 genome relative to the CWL029 genome are the absence of five DNA segments, ranging in size from 89 to 1649 nt, and the presence of three DNA segments, ranging from 27 to 84 nt. The complex organization of these 'different zones' may be attributable to a unique system of recombination.
- 15 June 2000
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 28 (12) , 2311-2314
Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA
Chlamydia pneumoniae is a widespread pathogen of humans causing pneumonia and bronchitis. There are many reports of an association between C.PNEUMONIAE: infection and atherosclerosis. We determined the whole genome sequence of C.PNEUMONIAE: strain J138 isolated in Japan in 1994 and compared it with the sequence of strain CWL029 isolated in the USA before 1987. The J138 circular chromosome consists of 1 226 565 nt (40.7% G+C) with 1072 likely protein-coding genes that is 3665 nt shorter than the CWL029 genome. Plasmids, phage- or transposon-like sequences were not identified. The overall genomic organization, gene order and predicted proteomes of the two strains are very similar, suggesting a high level of structural and functional conservation between the two unrelated isolates. The most conspicuous differences in the J138 genome relative to the CWL029 genome are the absence of five DNA segments, ranging in size from 89 to 1649 nt, and the presence of three DNA segments, ranging from 27 to 84 nt. The complex organization of these 'different zones' may be attributable to a unique system of recombination.
- Open Access
- 1 June 2000
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 181 (s3) , S524-S527
Comparison of Outer Membrane Protein Genesompandpmpin the Whole Genome Sequences ofChlamydia pneumoniaeIsolates from Japan and the United States
Chlamydia pneumoniae is a widespread pathogen of the respiratory tract that is also associated with atherosclerosis. The whole genome sequence was determined for a Japanese isolate, C. pneumoniae strain J138. The sequence predicted a variety of genes encoding outer membrane proteins (OMPs) including ompA and porB, another 10 predicted omp genes, and 27 pmp genes. All were detected in the whole genome sequence of strain CWL029, a strain isolated and sequenced in the United States. A comparative study of the OMPs of the two strains revealed a nucleotide sequence identity of 89.6%–100% (deduced amino acid sequence identity, 71.1%–100%). The overall genomic organization and location of genes are identical in both strains. Thus, a few unique sequences of the OMPs may be essential for specific attributes that define the differential biology of two C. pneumoniae strains.
- 1 June 2000
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 181 (s3) , S524-S527
Open AccessComparison of Outer Membrane Protein Genesompandpmpin the Whole Genome Sequences ofChlamydia pneumoniaeIsolates from Japan and the United States
Chlamydia pneumoniae is a widespread pathogen of the respiratory tract that is also associated with atherosclerosis. The whole genome sequence was determined for a Japanese isolate, C. pneumoniae strain J138. The sequence predicted a variety of genes encoding outer membrane proteins (OMPs) including ompA and porB, another 10 predicted omp genes, and 27 pmp genes. All were detected in the whole genome sequence of strain CWL029, a strain isolated and sequenced in the United States. A comparative study of the OMPs of the two strains revealed a nucleotide sequence identity of 89.6%–100% (deduced amino acid sequence identity, 71.1%–100%). The overall genomic organization and location of genes are identical in both strains. Thus, a few unique sequences of the OMPs may be essential for specific attributes that define the differential biology of two C. pneumoniae strains.
- 1 August 1998
- Vol. 44 (8) , 547-52
[Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
We conducted a prospective randomized controlled study on the prophylactic effects of short-term intravesical instillation of pirarubicin (THP) against recurrence to determine the effective administration schedule. All patients gave their informed consent. The subjects included bladder cancer patients who had pTa or pT1, and G1 or G2 cancer, and became tumor-free after transurethral resection of the bladder tumor (TUR-BT). After dissolving 30 mg of THP into 5 ml of distilled water, physiological saline was added to adjust the total volume to 50 ml, which was then instilled into the bladder, and was retained for 5 minutes. The schedule of instillation was for daily for 7 consecutive days from the day of TUR-BT and subsequently once a week for 10 weeks, 17 times in total for Group I, and once every two weeks for 6 months (12 times) starting 2 weeks after TUR and subsequently once a month until one year had passed after surgery (6 times), 18 times in total for Group II. The total number of cases was 69 (36 in Group I, 33 in Group II). The tumor-free ratios determined by the Kaplan-Meier analysis were 93.9% in Group I and 72.7% in Group II for one year, and 86.8% in Group I and 59.5% in Group II for two years. There was a statistically significant difference in the tumor-free ratios between the two groups by the generalized Wilcoxon test and the Log rank test (p = 0.0145 and 0.0107, respectively). Multivariated analysis using Cox's comparison hazard model produced p-values of 0.0002, 0.0007, 0.0009 and 0.0040 in the order of therapeutic mode, initial onset/recurrence, stage and number of tumor. Adverse events that forced discontinuation of the therapy for a while occurred in 4.3%. These results demonstrated that short-term intensive intravesical instillation of THP immediately after TUR-BT was a safe and effective therapy.
- 1 August 1998
- Vol. 44 (8) , 547-52
[Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
We conducted a prospective randomized controlled study on the prophylactic effects of short-term intravesical instillation of pirarubicin (THP) against recurrence to determine the effective administration schedule. All patients gave their informed consent. The subjects included bladder cancer patients who had pTa or pT1, and G1 or G2 cancer, and became tumor-free after transurethral resection of the bladder tumor (TUR-BT). After dissolving 30 mg of THP into 5 ml of distilled water, physiological saline was added to adjust the total volume to 50 ml, which was then instilled into the bladder, and was retained for 5 minutes. The schedule of instillation was for daily for 7 consecutive days from the day of TUR-BT and subsequently once a week for 10 weeks, 17 times in total for Group I, and once every two weeks for 6 months (12 times) starting 2 weeks after TUR and subsequently once a month until one year had passed after surgery (6 times), 18 times in total for Group II. The total number of cases was 69 (36 in Group I, 33 in Group II). The tumor-free ratios determined by the Kaplan-Meier analysis were 93.9% in Group I and 72.7% in Group II for one year, and 86.8% in Group I and 59.5% in Group II for two years. There was a statistically significant difference in the tumor-free ratios between the two groups by the generalized Wilcoxon test and the Log rank test (p = 0.0145 and 0.0107, respectively). Multivariated analysis using Cox's comparison hazard model produced p-values of 0.0002, 0.0007, 0.0009 and 0.0040 in the order of therapeutic mode, initial onset/recurrence, stage and number of tumor. Adverse events that forced discontinuation of the therapy for a while occurred in 4.3%. These results demonstrated that short-term intensive intravesical instillation of THP immediately after TUR-BT was a safe and effective therapy.